Project Grant R01AI192152
Award Date
5/22/25
Completion Date
4/30/30
Dollars Obligated
$820K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $238,787 to support research on the mechanism of ESX-1 secretion in mycobacteria, including pathogens like Mycobacterium tuberculosis and Mycobacterium marinum. The research aims to overcome current limitations in localizing proteins to specific subcellular compartments, in order to elucidate the hierarchical...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,413,412 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Texas Biomedical Research Institute. The grant, titled "Mechanisms of Efficient Control of Mycobacterium Tuberculosis in the Lungs Prior to Granuloma," aims to develop novel vaccination strategies to contain the tuberculosis pandemic. The research will use cutting-edge techniques like single-cell RNA...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $787,171 to develop a new class of anti-tuberculosis (TB) compounds. The award supports research to discover and optimize 1,2,4-triazole and pyrrolidine compounds that inhibit the growth of drug-resistant strains of Mycobacterium tuberculosis, the causative agent of TB. The research aims to understand the...
This $2,817,044 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports a research program titled "Systems Genetics of Tuberculosis". The program aims to leverage new mouse and bacterial genetic resources to study the complex interactions between host diversity and pathogen variation that influence tuberculosis (TB) infection outcomes and vaccine efficacy. Key products and services to be...
This $749,192 federal Project Grant award was made by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant will fund research to compare the protective efficacy and host immune responses of different BCG vaccine sub-strains in animal models and correlate these findings with responses in BCG-vaccinated humans. The goal is to better understand the molecular basis for differences in vaccine-induced...
This $176,152 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify new drug targets for treating drug-tolerant strains of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The research aims to investigate how alterations in lipid metabolism and host-pathogen interactions contribute to drug tolerance in MTB strains with...
This federal Project Grant award, valued at $899,894 and awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports scientific research on understanding the interactions between macrophages, neutrophils, and HIV that contribute to tuberculosis (TB) disease progression. The key products and services to be delivered under this grant include: Defining the type I interferon (IFN) signaling and...
This federal Project Grant award, valued at $774,881, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant aims to develop pro-apoptotic (cell death-inducing) drugs as host-directed therapies to shorten treatment for drug-susceptible and multi-drug resistant pulmonary tuberculosis (TB), as well as prevent post-TB lung disease. The project will leverage advanced in vivo imaging...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support a research project to determine the value of the ESAT-6 antigen in Mycobacterium tuberculosis (MTB) infection and vaccine development. The $278,390 award, with a period of performance from February 1, 2025 to January 31, 2027, will enable researchers at the University of California, San Francisco (UCSF) to generate...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $565,149 to Health Research, Inc. Wadsworth Center Division to conduct research on RNA-based regulatory mechanisms in Mycobacterium tuberculosis (MTB). The primary objectives are to: Define the regulatory interactions of the sRNA MCR11 and its impact on gene expression in MTB. Characterize the roles of RNA-ABMR...